Fatty acid-like Pt(<scp>iv</scp>) prodrugs overcome cisplatin resistance in ovarian cancer by harnessing CD36
Amarasooriya M. D. S. Jayawardhana, Morgan Stilgenbauer, Payel Datta, Zihan Qiu, Sarine Mckenzie, Han Wang, David J. Bowers, Manabu Kurokawa, Yao‐Rong Zheng
Abstract
Resistance to the platinum-based chemotherapy drug, cisplatin, is a significant setback in ovarian cancer. We engineered fatty acid-like Pt(iv) prodrugs that harness the fatty acid transporter CD36 to facilitate their entry to ovarian cancer cells. We show that these novel constructs effectively kill cisplatin-resistant ovarian cancer cells.
Topics & Concepts
ProdrugCisplatinCD36ChemistryOvarian cancerCancer researchPharmacologyBiochemistryCancerInternal medicineMedicineChemotherapyGeneMetal complexes synthesis and propertiesPeptidase Inhibition and AnalysisRNA modifications and cancer